The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksABC.L Regulatory News (ABC)

  • There is currently no data for ABC

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Pricing of Offering on NASDAQ

22 Oct 2020 07:00

RNS Number : 8513C
ABCAM PLC
22 October 2020
 

Abcam plc

 

 THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO 596/2014

 

Abcam Announces Pricing of Offering on NASDAQ

 

October 22, 2020, London - Abcam plc (AIM: ABC) ("Abcam"), a global leader in the supply of life science research tools, announces today the pricing of its offering of 8,945,218 American Depositary Shares ("ADSs"), representing an aggregate of 8,945,218 ordinary shares, at a price of $17.50 per ADS, for aggregate proceeds of approximately $156.5 million, before deducting underwriting discounts and commissions. Each ADS offered represents one ordinary share of Abcam. The ADSs are being offered in a registered public offering in the United States (the "Offering").

 

In addition, Abcam has granted the underwriters a 30-day option to purchase up to an additional 1,341,782 ADSs on the same terms and conditions.

 

The closing of the Offering is expected to occur on October 26, 2020, subject to customary closing conditions.

 

Abcam's ordinary shares are admitted to trading on the AIM market of the London Stock Exchange under the symbol "ABC." The ADSs have been approved for listing on the NASDAQ Global Market ("NASDAQ") and are expected to begin trading under the symbol "ABCM" on October 22, 2020.

 

Morgan Stanley and BofA Securities are acting as the lead book-running managers for the Offering. SVB Leerink is acting as a book-running manager, and Lazard and William Blair are acting as co-managers.

 

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on October 21, 2020. The Offering is being made only by means of a prospectus. When available, copies of the final prospectus relating to and describing the terms of the Offering may be obtained from the offices of Morgan Stanley, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014; or from BofA Securities, Attention: Prospectus Department, 200 North College Street, 3rd Floor, Charlotte, North Carolina 28255-0001, or by email at dg.prospectus_requests@bofa.com.

 

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction.

 

Forward Looking Statements

 

This press release contains forward-looking statements. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding Abcam's plans to conduct the Offering.

 

These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees but involve known and unknown risks, uncertainties and other important factors that may cause Abcam's actual results, performance or achievements to be materially different from its expectations expressed or implied by the forward-looking statements, including, but not limited to, the following: Abcam may determine not to conduct a registered initial public offering in the time frame that it currently expects or at all, due to a number of potential important factors, including conditions in the U.S. capital markets, negative global economic conditions, potential negative developments in the COVID-19 pandemic, other negative developments in Abcam's business or unfavorable legislative or regulatory developments.

 

These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While Abcam may elect to update such forward-looking statements at some point in the future, Abcam disclaims any obligation to do so, even if subsequent events cause its views to change. These forward-looking statements should not be relied upon as representing Abcam's views as of any date subsequent to the date of this press release.

 

For readers in the European Economic Area and the United Kingdom

 

There will be no public offer of the ADSs to the public in the European Economic Area or the United Kingdom.

 

This communication , in so far as it constitutes an invitation or inducement to enter into investment activity within the meaning of section 21 of the Financial Services and Markets Act 2000 as amended ("FSMA") in connection with the securities which are the subject of the offering described in this press release or otherwise, is only being directed at: (a) in the European Economic Area (the "EEA"), persons who are qualified investors within the meaning of Article 2(e) of Prospectus Regulation (EU) 2017/1129 (the "Prospectus Regulation") ("Qualified Investors"); and (b) in the United Kingdom, Qualified Investors who are (i) persons who fall within the definition of "Investment Professionals" in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "Order"); or (ii) persons who fall within Article 49(2)(a) to (d) ("High net worth companies, unincorporated associations etc.") of the Order; or (c) persons to whom it may otherwise be lawfully communicated (all such persons referred to in (a), (b) and (c) above together being referred to as "Relevant Persons").

 

The ADSs offered in the Offering are only available to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such ADSs will be engaged in only with, in the EEA and the United Kingdom, Relevant Persons. Any person who, in the EEA or the United Kingdom, is not a Relevant Person should not act or rely on this document or any of its contents. This communication does not contain an offer or constitute any part of an offer to the public within the meaning of sections 85 and 102B of FSMA or otherwise.

 

 

For further information, please contact:

Abcam

 

+ 44 (0) 1223 696 000

James Staveley, Vice President, Investor Relations

 

Numis - Nominated Advisor & Joint Corporate Broker

+ 44 (0) 20 7260 1000

Garry Levin / Duncan Monteith / Huw Jeremy

 

J.P. Morgan Cazenove - Joint Corporate Broker

+ 44 (0) 20 7742 4000

James Mitford / Hemant Kapoor

 

Morgan Stanley - Joint Corporate Broker

+ 44 (0) 207 425 8000

Tom Perry / Luka Kezic

 

FTI Consulting

+ 44 (0) 20 3727 1000

Ben Atwell / Natalie Garland-Collins

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCPPGGAUUPUPGG
Date   Source Headline
16th Sep 20198:02 amRNSDirector/PDMR Shareholding
12th Sep 20197:00 amRNSNotice of Capital Markets Event
11th Sep 201910:33 amRNSDirector/PDMR Shareholding
11th Sep 201910:11 amRNSReplacement: Director/PDMR Shareholding
11th Sep 20197:00 amRNSDirector/PDMR Shareholding
9th Sep 20197:00 amRNSFull year results for 12 months ended 30 June 2019
2nd Sep 20193:14 pmRNSTotal Voting Rights
1st Aug 201912:10 pmRNSTotal Voting Rights
22nd Jul 20197:01 amRNSDirectorate Change
22nd Jul 20197:00 amRNSFull Year Trading Update
16th Jul 20197:00 amRNSAcquisition of Cell Lines and Lysates Portfolio
1st Jul 20199:38 amRNSTotal Voting Rights
3rd Jun 201910:45 amRNSTotal Voting Rights
2nd May 201912:53 pmRNSTotal Voting Rights
1st May 20197:00 amRNSAppointment of Joint Broker
2nd Apr 20191:13 pmRNSTotal Voting Rights
29th Mar 20197:00 amRNSCompany Secretary Change
12th Mar 20197:00 amRNSHolding(s) in Company
8th Mar 20198:57 amRNSHolding(s) in Company
4th Mar 20197:00 amRNSInterim results for six months ended 31 Dec 2018
1st Mar 201910:29 amRNSTotal Voting Rights
25th Feb 20195:39 pmRNSChange of Registered Office
18th Feb 20191:01 pmRNSBlock listing Interim Review
5th Feb 201911:34 amRNSTotal Voting Rights
28th Jan 20197:00 amRNSAcquisition of Calico Biolabs
8th Jan 20197:00 amRNSHalf Year Trading Update
3rd Jan 20191:45 pmRNSTotal Voting Rights
3rd Jan 20197:00 amRNSAbcam to present at J.P. Morgan Conference
13th Dec 201810:06 amRNSDirectorate Change
6th Dec 20181:06 pmRNSDirector/PDMR Shareholding
3rd Dec 20184:02 pmRNSDirector/PDMR Shareholding
3rd Dec 201812:21 pmRNSTotal Voting Rights
12th Nov 20181:59 pmRNSDirector/PDMR Shareholding
8th Nov 20189:32 amRNSDirector/PDMR Shareholding
6th Nov 20185:47 pmRNSResult of AGM
2nd Nov 20188:51 amRNSTotal Voting Rights
1st Nov 20181:22 pmRNSHolding(s) in Company
29th Oct 20188:57 amRNSDirector/PDMR Shareholding
10th Oct 201810:46 amRNSHolding(s) in Company
9th Oct 20188:59 amRNSDirector/PDMR Shareholding
2nd Oct 201812:54 pmRNSHolding(s) in Company
2nd Oct 201812:51 pmRNSDirector/PDMR Shareholding
1st Oct 20185:41 pmRNSTotal Voting Rights
28th Sep 201810:11 amRNSDirector/PDMR Shareholding
24th Sep 20182:42 pmRNSHolding(s) in Company
21st Sep 201812:56 pmRNSAnnual Financial Report
14th Sep 20189:46 amRNSDirector/PDMR Shareholding
13th Sep 20181:34 pmRNSDirector/PDMR Shareholding
13th Sep 20181:33 pmRNSDirector/PDMR Shareholding
11th Sep 201810:30 amRNSDividend Payment Date

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.